Dexrazoxane
Tóm tắt
Dexrazoxane has been used successfully to reduce cardiac toxicity in patients receiving anthracycline-based chemotherapy for cancer (predominantly women with advanced breast cancer). The drug is thought to reduce the cardiotoxic effects of anthracyclines by binding to free and bound iron, thereby reducing the formation of anthracycline-iron complexes and the subsequent generation of reactive oxygen species which are toxic to surrounding cardiac tissue. Clinical trials in women with advanced breast cancer have found that patients given dexrazoxane (about 30 minutes prior to anthracycline therapy; dexrazoxane to doxorubicin dosage ratio 20: 1 or 10: 1) have a significantly lower overall incidence of cardiac events than placebo recipients (14 or 15% vs 31%) when the drug is initiated at the same time as doxorubicin. Cardiac events included congestive heart failure (CHF), a significant reduction in left ventricular ejection fraction and/or a ≥2-point increase in the Billingham biopsy score. These results are supported by the findings of studies which used control groups (patients who received only chemotherapy) for comparison. The drug appears to offer cardiac protection irrespective of pre-existing cardiac risk factors. In addition, cardiac protection has been shown in patients given the drug after receiving a cumulative doxorubicin dose ≥300 mg/m2. It remains to be confirmed that dexrazoxane does not affect the antitumour activity of doxorubicin: although most studies found that clinical end-points (including tumour response rates, time to disease progression and survival duration) did not differ significantly between treatment groups, the largest study did show a significant reduction in response rates in dexrazoxane versus placebo recipients. Dexrazoxane permits the administration of doxorubicin beyond standard cumulative doses; however, it is unclear whether this will translate into prolonged survival. Preliminary results (from small nonblind studies) indicate that dexrazoxane reduces cardiac toxicity in children and adolescents receiving anthracycline-based therapy for a range of malignancies. The long term benefits with regard to prevention of late-onset cardiac toxicity remain unclear. With the exception of severe leucopenia [Eastern Cooperative Oncology Group (ECOG) grade 3/4 toxicity], the incidence of haematological and nonhaema-tological adverse events appears similar in patients given dexrazoxane to that in placebo recipients undergoing anthracycline-based chemotherapy. Although preliminary pharmacoeconomic analyses have shown dexrazoxane to be a costeffective agent in women with advanced breast cancer, they require confirmation.
Conclusions: Dexrazoxane is a valuable drug for protecting against cardiac toxicity in patients receiving anthracycline-based chemotherapy. Whether it offers protection against late-onset cardiac toxicity in patients who received anthracycline-based chemotherapy in childhood or adolescence remains to be determined. Further clinical experience is required to confirm that it does not adversely affect clinical outcome, that it is a cost-effective option, and to determine the optimal treatment regimen. The use of anthracyclines is significantly limited by cardiac toxicity, which occurs in 1 to 2% of patients given a cumulative doxorubicin dose < 450 mg/m2. This increases to 20 to 40% at cumulative doses >600 mg/m2. Children appear to be more susceptible to the cardiotoxic effects of this class of drugs than adults, although toxicity may not become apparent until years after cessation of therapy. Cardiac toxicity is thought to occur principally as a result of oxidative stress placed on cardiac myocytes by reactive oxygen species (generated by the stable complex formed between anthracyclines and iron). Consequently, the ability of free-radical scavengers and metal-chelating agents to reduce cardiac toxicity has been investigated. Dexrazoxane, a cyclic derivative of edetic acid (EDTA), provides cardiac protection from anthracyclines primarily through its metal-chelating activity. The hydrolysis products of dexrazoxane have been shown to chelate both free and bound intracellular iron, including iron that is bound in anthracycline complexes, thereby preventing the generation of cardiotoxic reactive oxygen species. The hydrolysis products are thought to be responsible for most of the activity of the drug. The cardioprotective activity of dexrazoxane has been demonstrated in animal models of anthracycline-induced cardiac toxicity. Dexrazoxane administration was associated with a significant reduction in the number of cardiac lesions and increased survival after toxic doses of anthracyclines. In studies in beagle dogs and rats, the drug appeared more effective when administered prior to or simultaneously with the anthracycline. In addition, delayed administration until after the sixth dose of doxorubicin was less effective than administration at the time of the initial doxorubicin dose (in contrast, delayed administration did not appear to reduce dexrazoxane's cardioprotective effect in patients). Studies in patients receiving anthracycline therapy for cancer indicate that the pharmacokinetic properties of dexrazoxane fit a 2-compartment model with first-order elimination kinetics. Absorption is linear within the dose range 60 to 900 mg/m2: the mean peak plasma concentration is 36.5 mg/L after a 15-minute intravenous infusion of dexrazoxane 500 mg/m2. The distribution half-life is about 15 minutes and the steady-state volume of distribution has been estimated to be about 1.1 L/kg. Protein binding is usually <2%. Dexrazoxane is hydrolysed to its active ring-opened forms by the enzyme dihydropyrimidine amidohydrolase (DHPase). Unchanged dexrazoxane, a diacid-diamide cleavage product and 2 monoacid-monoamide ring products have been detected in the urine. Total body clearance is about 0.29 L/h/kg. Most of the drug is eliminated in the urine (about 50% over 24 hours), the elimination half-life ranging from 2 to 4 hours. A study comparing the pharmacokinetic properties of dexrazoxane in adults and children found that the steady-state volume of distribution was higher in children, as was the total body clearance rate. There are no data at present on the properties of the drug in patients with renal or hepatic impairment. The pharmacokinetic properties of doxorubicin (60 mg/m2) are generally unchanged when the drug is administered 15 to 30 minutes after dexrazoxane (600 o 900 mg/m2) intravenous infusion. However, the properties of epirubicin may be altered by dexrazoxane when the drug is administered at doses ≥100 mg/m2. Clinical trials have shown dexrazoxane to significantly reduce the incidence of cardiac toxicity in patients receiving anthracycline-based chemotherapy for advanced breast cancer. Cardiac events indicative of cardiac toxicity included congestive heart failure (CHF), a reduction in the resting left ventricular ejection fraction (LVEF) to <45% or a ≥20% reduction in LVEF from baseline and/or a ≥2 point increase in the Billingham biopsy score. In these studies, the dexrazox-ane to doxorubicin dosage ratio was 10: 1 or 20: 1. In 2 multicentre double-blind comparative studies, the incidence of doxorubicin (50 mg/m2)-induced cardiac toxicity was 15 and 14% in patients given dexrazoxane (500 mg/m2 about 30 minutes prior to each dose of the anthracycline) versus 31% in both groups of placebo recipients. CHF occurred in 15% of placebo recipients but in no patients treated with dexrazoxane in one of these studies. Where reported in comparative studies, clinically relevant reductions in LVEF were less common in patients treated with dexrazoxane than in dexrazoxane-untreated control patients or placebo recipients. In most studies, dexrazoxane therapy was started at the same time as anthracycline therapy; however, it may also be cardioprotective when administration is delayed until a cumulative dose of doxorubicin ≥300 mg/m2 has been given (incidence of cardiac events 60% in patients given placebo throughout (for up to 13 cycles of chemotherapy) versus 25% in patients initially given placebo (for 6 cycles of chemotherapy) then switched to dexrazoxane according to protocol amendment). The extent of cardiac protection offered by dexrazoxane appeared similar in patients with or without pre-existing cardiac risk factors. Dexrazoxane did not affect the clinical outcome of anthracycline therapy in most studies. However, the largest study did show a significantly lower rate of tumour response to doxorubicin therapy in patients given dexrazoxane versus that in placebo recipients (46.8 vs 60.5%). Other studies (including one by the same investigators) have failed to show any detrimental effect of dexrazoxane on the antitumour activity of anthracyclines. The cardiac protection offered by dexrazoxane permits the administration of doxorubicin beyond standard cumulative doses. However, it remains unclear whether this will prolong the time to disease progression or the overall survival duration. While there was a trend towards prolonged survival in dexrazoxane recipients in most studies, the difference did not reach statistical significance (except in a retrospective analysis of patients given placebo or placebo followed by dexrazoxane as a result of protocol amendment). Preliminary results (from small nonblind studies) indicate that dexrazoxane is also an effective cardioprotective agent in children and adolescents receiving anthracycline-based chemotherapy for a range of malignancies: the incidence of cardiac toxicity was 22 vs 67% in dexrazoxane-treated and -untreated patients in one study. Further investigation in this high-risk patient group, with regard to long term benefit, is warranted. Available data from clinical trials in women with advanced breast cancer indicate that coadministration of dexrazoxane with anthracycline-based chemotherapy does not compromise tolerability in most patients. As expected, haematological toxicity was common in all treatment groups, but was generally more frequent in patients given dexrazoxane than in control groups (either placebo or no additional treatment). In comparisons with placebo, the incidence of severe leucopenia [Eastern Cooperative Oncology Group (ECOG) grade 3/4] at nadir was significantly higher in dexrazoxane recipients (78 vs 68%; p < 0.01). However, the incidences of severe granulocytopenia and thrombocytopenia did not differ significantly between treatment groups. The incidence and nature of other adverse events including vomiting, mucositis, infection, fever with neutropenia, alopecia, diarrhoea, fatigue, anaemia, haemorrhage, sepsis and stomatitis were similar between treatment groups. Pain on injection was more common with dexrazoxane than with placebo, whereas severe nausea (ECOG grade 3/4) appeared more common with placebo in comparative trials. Limited data indicate that the drug has similar tolerability in children and adolescents to that observed in women with advanced breast cancer. Pharmacoeconomic analyses [based on data from a retrospective study of patients with breast cancer given placebo for up to 13 cycles of chemotherapy or placebo for 6 cycles then dexrazoxane (as a result of protocol amendment in 2 phase III studies)] indicate that the administration of dexrazoxane to prevent anthracycline-induced cardiac toxicity was cost-effective. Dexrazoxane cost $US5662 per cardiac event prevented and $US12 992 per CHF event prevented (based on 1995 costs). It was also found to cost $US2809 per life-year gained; however, survival data used in this analysis require confirmation. The investigators concluded that dexrazoxane compared well in terms of cost-effectiveness with other medical interventions in routine use in the US and Canada, including invasive cardiac monitoring to prevent heart failure. For protection against anthracycline-induced cardiac toxicity, the recommended dexrazoxane to anthracycline dosage ratio is 10: 1 in the US (i.e. 500 mg/m2 for a 50 mg/m2 doxorubicin dose) or 20: 1 in Europe. Dexrazoxane should be administered by intravenous infusion (slow push or rapid drip infusion), starting approximately 30 minutes before anthracycline infusion. In Europe, dexrazoxane should be initiated at the same time as anthracycline therapy whereas in the US delayed administration until a cumulative dose of 300 mg/m2 doxorubicin is given is recommended. The maximum dose given in any cycle should not exceed 1000 mg/m2. Dexrazoxane may potentiate haematological toxicity induced by chemotherapy or radiation; thus monitoring of haematological parameters is recommended. The drug should not be given to pregnant or breast-feeding women, and caution is required in patients with renal or liver impairment.
Tài liệu tham khảo
Von Hoff DD, Rozencweig M, Piccart M. The cardiotoxicity of anticancer agents. Semin Oncol 1982; 9: 23–33
Praga C, Beretta G, Vigo PL, et al. Adriamycin cardiotoxicity: a survey of 1273 patients. Cancer Treat Rep 1979; 63: 827–34
Von Hoff DD, Rozencweig M, Layard M, et al. Daunomycin-induced cardiotoxicity in children and adults: a review of 110 cases. Am J Med 1977; 62: 200–8
Dearth J, Osborn R, Wilson E, et al. Anthracycline-induced cardiomyopathy in children: a report of six cases. Med Pediatr Oncol 1984; 12: 54–8
Unverferth DV, Magorien RD, Leier CV, et al. Doxorubicin cardiotoxicity. Cancer Treat Res 1983; 9: 149–64
Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91: 710–7
Swain SM, Whaley FS, Gerber MC, et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 1997 Apr; 15: 1318–32
Blum RH. Clinical status and optimal use of the cardioprtectant dexrazoxane. Oncology 1997; 11: 1669–78
Lipschultz SE, Colan SD, Gelber RD, et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991; 324: 808–15
Lipschultz SE. Dexrazoxane for protection against cardiotoxic effects of anthracyclines in children. J Clin Oncol 1996; 14: 326–31
Chiron BV Cardioxane product monograph. Amsterdam, The Netherlands, 1995
Handa K, Sato S. Generation of free radicals of quinone group containing anti-cancer chemicals in NADPH-microsome system as evidenced by initiation of sulfite oxidation. Jpn J Cancer Res 1975; 66: 43–75
Pigram WJ, Fuller W, Hamilton LDH. Stereochemistry of intercalation: interaction of daunomycin with DNA. Nature 1972; 235: 17–9
Myers CE, Gianni L, Zweier J, et al. The role of iron in adriamycin biochemistry. Fed Proc 1986; 1986: 2792–7
Myers CE, McGuire WP, Liss RH, et al. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science 1977; 197: 165–7
Weijl NI, Cleton FJ, Osanto S. Free radicals and antioxidants in chemotherapy-induced toxicity. Cancer Treat Rev 1997 Jul; 23: 209–40
Hasinoff BB, Hellmann K, Herman EH, et al. Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines. Curr Med Chem 1998; 5: 1–28
Doroshow JH, Locker GY, Baldinger J, et al. The effect of doxorubicin on hepatic and cardiac glutathione. Res Commun Chem Pathol Pharmacol 1979; 26: 285–95
Doroshow JH, Locker GY, Myers CE. Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. J Clin Invest 1980; 65: 128–35
Sugioka KA, Nakano M. Mechanisms of phospholipid peroxidation induced by ferric iron-ADP adriamycin co-ordination complex. Biochem Biophys Res Commun 1982; 713: 333–43
Legha S, Wang Y-M, Mackay B, et al. Clinical and pharmacological investigation of the effects of α-tocopherol on adriamycin cardiotoxicity. Ann N Y Acad Sci 1982; 393: 411–8
Myers CE, Bonow R, Palmeri S, et al. A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine. Semin Oncol 1983; 10 Suppl. l: 53–5
Hasinoff BB, Kala SV. The removal of metal ions from transferrin, ferritin and ceruloplasmin by the cardioprotective agent ICRF-187 [(+)-l,2-bis(3,5-dioxopiperazinyl-l-yl)propane] and its hydrolysis product ADR-925. Agents Actions 1993 May; 39: 72–81
Hasinoff BB. The interaction of the cardioprotective agent ICRF-187 ((+)-l,2-bis(3,5-dioxopiperazinyl-l-yl)propane); its hydrolysis product (ICRF-198); and other chelating agents with the Fe(III) and Cu(II) complexes of adriamycin. Agents Actions 1989 Mar; 26(3-4): 378–85
Buss JL, Hasinoff BB. The one-ring open hydrolysis product intermediates of the cardioprotective agent ICRF-187 (dexrazoxane) displace iron from iron-anthracycline complexes. Agents Actions 1993 Sep; 40: 86–95
Hüsken BC, de Jong J, Beekman B, et al. Modulation of the in vitro cardiotoxicity of doxorubicin by flavonoids. Cancer Chemother Pharmacol 1995; 37: 55–62
Yeung TK, Jaenke RS, Wilding D, et al. The protective effect of ICRF-187 against doxorubicin-induced cardiotoxicity in the rat. Cancer Chemother Pharmacol 1992 May; 30: 58–64
Alderton PM, Gross J, Green MD. Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model. Cancer Res 1992 Jan 1; 52: 194–201
Herman EH, Zhang J, Ferrans VJ. Comparison of the protective effects of desferrioxamine and ICRF-187 against doxorubicin-induced toxicity in spontaneously hypertensive rats. Cancer Chemother Pharmacol 1994 Dec; 35: 93–100
Herman EH, Zhang J, Hasinoff BB, et al. Comparison of the protective effects against chronic doxorubicin cardiotoxicity and the rates of iron (III) displacement reactions of ICRF-187 and other bisdiketopiperazines. Cancer Chemother Pharmacol 1997 Sep; 40: 400–8
Imondi AR, Delia Torre P, Mazué G, et al. Dose-response relationship of dexrazoxane for prevention of doxorubicin-induced cardiotoxicity in mice, rats, and dogs. Cancer Res 1996 Sep 15; 56: 4200–4
van-Acker SA, Kramer K, Voest EE, et al. Doxorubicin-induced cardiotoxicity monitored by ECG in freely moving mice: a new model to test potential protectors. Cancer Chemother Pharmacol 1996; 38: 95–101
Villani F, Galimberti M, Monti E, et al. Effect of ICRF-187 pretreatment against doxorubicin-induced delayed cardiotoxicity in the rat. Toxicol Appl Pharmacol 1990 Feb; 102: 292–9
Agen C, Bernardini N, Danesi R, et al. Reducing doxorubicin cardiotoxicity in the rat using deferred treatment with ADR-529. Cancer Chemother Pharmacol 1992 Jun; 30: 95–9
Herman EH, Ferrans VJ. Pretreatment with ICRF-187 provides long-lasting protection against chronic daunorubicin cardiotoxicity in rabbits. Cancer Chemother Pharmacol 1986; 16: 102–6
Pouna P, Bonoron-Adèle S, Gouverneur G, et al. Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention. Br J Pharmacol 1996 Apr; 117: 1593–9
Herman EH, Ferrans VJ. Timing of treatment with ICRF-187 and its effect on chronic doxorubicin cardiotoxicity. Cancer Chemother Pharmacol 1993; 32: 445–9
Holcenberg JS, Tutsch KD, Earhart RH, et al. Phase I study of ICRF-187 in pediatric cancer patients and comparison of its pharmacokinetics in children and adults. Cancer Treat Rep 1986 Jun; 70: 703–9
Vogel CL, Gorowski E, Davila E, et al. Phase I clinical trial and pharmacokinetics of weekly ICRF-187 (NSC 169780) infusion in patients with solid tumors. Invest New Drugs 1987; 5: 187–98
Earhart RH, Tutsch KD, Koeller JM, et al. Pharmacokinetics of (+)-l,2-Di(3,5-dioxopiperazin-l-yl)propane intravenous infusions in adult cancer patients. Cancer Res 1982; 42: 5255–61
Hochster H, Liebes L, Wadler S, et al. Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin. J Natl Cancer Inst 1992 Nov 18; 84: 1725–30
Pharmacia and Upjohn Company. Zinecard (dexrazoxane for injection) prescribing information. Kalamazoo, MI, USA, 1996
Hasinoff BB. Enzymatic ring-opening reactions of the chiral cardioprotective agent (+) (S)-ICRF-187 and its (-) (R)-enantiomer ICRF-186 by dihydropyrimidine amidohydrolase. Drug Metab Dispos 1993 Sep–Oct; 21: 883–8
Hasinoff BB. Stereoselective hydrolysis of ICRF-187 (dexrazoxane) and ICRF-186 by dihydropyrimidine amidohydrolase. Chirality 1994; 6: 213–5
Hasinoff BB. Pharmacodynamics of the hydrolysis-activation of the cardioprotective agent (+)-l,2-bis(3,5-dioxopiper-azinyl-l-yl)propane. J Pharm Sci 1994 Jan; 83: 64–7
Robert J, Bellott R, Debled M, et al. Lack of interference of dexrazoxane on the pharmacokinetics of doxorubicin in cancer patients [abstract no 960]. Proceedings of the American Society of Oncology 1998; 17: 250a
Basser RL, Sobol MM, Duggan G, et al. Comparative study of the pharmacokinetics and toxicity of high-dose epirubicin with or without dexrazoxane in patients with advanced malignancy. J Clin Oncol 1994 Aug; 12: 1659–66
Jakobsen P, Sorensen B, Bastholt L, et al. The pharmacokinetics of high-dose epirubicin and of the cardioprotector ADR-529 given together with cyclophosphamide, 5-fluorouracil, and tamoxifen in metastatic breast-cancer patients. Cancer Chemother Pharmacol 1994; 35: 45–52
Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649–55
Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981; 47: 207–14
Piga A, Francini G, Pein F, et al. Cardioprotection by Cardioxane® (dexrazoxane) in breast cancer patients at increased risk for anthracycline-induced cardiotoxicity [abstract]. 84th Annual Meeting of the American Association of Cancer Resea-arch 1993 Mar; 34: 228
Neijens V, ten Hoeve R, Valdes Olmos R, et al. Feasibility study of the combination of high dose epirubicin and cyclophosphamide and G-CSF every two weeks together with ICRF 187 [abstract]. Ann Oncol 1994; 5 Suppl. 5: 182
Kassianenko I, Pivnjuk V, Tarutinov V, et al. The role of cardiotoxicity protector cardioxane combined with chemotherapy with doxorubicin in advanced breast cancer [abstract]. 2nd European Congress of the Senologic International Society 1994: 52
Maral J, Vinke J, Oskam R, et al. Cardioxane still induces effective cardioprotection in anthracycline pretreated breast cancer patients [abstract]. Eur J Cancer A 1996; 32A Suppl. 2: 48
Orditura M, De Rimini ML, Ciaramella F, et al. Is ICRF-187 effective against doxorubicin induced cardiotoxicity? [abstract]. Med Microbiol Lett 1996 May; 5 Suppl. 1: S107
Kolaric K, Bradamante V, Cervek J, et al. A phase II trial of cardioprotection with cardioxane (ICRF-187) in patients with advanced breast cancer receiving 5-fluorouracil, doxorubicin and cyclophosphamide. Oncology 1995 May–Jun; 52: 251–5
Lopez M, Vici P, Di Lauro L, et al. Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas. J Clin Oncol 1998 Jan; 16: 86–92
Speyer JL, Green MD, Kramer E, et al. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med 1988 Sep 22; 319: 745–52
Swain SM, Whaley FS, Gerber MC, et al. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J Clin Oncol 1997 Apr; 15: 1333–40
Venturini M, Michelotti A, Del Mastro L, et al. Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. J Clin Oncol 1996 Dec; 14: 3112–20
Speyer JL, Green MD, Zeleniuch-Jacquotte A, et al. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 1992 Jan; 10: 117–27
Jelić S, Radulović S, Nešković-Konstantinovic Z, et al. Cardioprotection with ICRF-187 (Cardioxane) in patients with advanced breast cancer having cardiac risk factors for doxorubicin cardiotoxicity, treated with the FDC regimen. Support Care Cancer 1995 May; 3: 176–82
Steinherz LJ, Steinherz PG, Tan CTC, et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991; 266: 1672–7
Lemež P, Marešová J. Protective effects of cardioxane against anthracycline-induced cardiotoxicity in relapsed acute myeloid leukemias. Neoplasma 1996; 43(6): 417–9
Schuler D, Horváth E, Koós R, et al. Safety of dexrazoxane in children with ALL undergoing anthracycline therapy: preliminary results of a prospective pilot study. Pediatr Hematol Oncol 1997 Jan–Feb; 14: 93–4
Schiavetti A, Castello MA, Versacci P, et al. Use of ICRF-187 for prevention of anthracycline cardiotoxicity in children: preliminary results. Pediatr Hematol Oncol 1997 May–Jun; 14: 213–22
Wexler LH, Andrich MP, Venzon D, et al. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol 1996 Feb; 14: 362–72
Rubio ME, Wiegman A, Naeff MSJ, et al. ICRF-187 protection against doxorubicin induced cardiomyopathy in paediatric osteosarcoma patients [abstract]. Med Pediatr Oncol 1995 Oct; 25: 292
Bu'Lock FA, Gabriel HM, Oakhill A, et al. Cardioprotection by ICRF187 against high dose anthracycline toxicity in children with malignant disease. Br Heart J 1993 Aug; 70: 185–8
Bates M, Lieu D, Zagari M, et al. A pharmacoeconomic evaluation of the use of dexrazoxane in preventing anthracycline-induced cardiotoxicity in patients with stage IIIB or IV metastatic breast cancer. Clin Ther 1997 Jan–Feb; 19: 167–84
Bates M, Tasch R, Williamson T, et al. Cost effectiveness of dexrazoxane cardioprotection in patients receiving FAC chemotherapy: a comparison between the US and Canada [abstract]. 13th Annual International Meeting of the International Society of Technology Assessment in Health Care 1997 May 25: 137
Picci P, Ferrari S, Bacci G, et al. Treatment recommendations for osteosarcoma and adult soft tissue sarcomas. Drugs 1994; 47: 82–92
Dombernowski P, Gehl J, Boesgaard M, et al. Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer. Semin Oncol 1996; 11 Suppl. 11: 23–7
Dombernowski P, Boesgard M, Andersen E, et al. Doxorubicin plus paclitaxel in advanced breast cancer. Semin Oncol 1997; 24 Suppl. 17: 15–8
Gianni L, Munzone E, Capri G, et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumour efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 1995; 1995: 2688–99